The approval two CAR T-cell therapies for relapsed / refractory B-cell hematological malignancies—Novatis’ Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite Pharma / Gilead’s Yescarta for large B-cell lymphoma—heralded a new era in cancer immunotherapy. Multiple myeloma, another hematological malignancy, is set to follow suit in 2021 and 2022 with the expected approval of BCMA-targeting CAR T-cell therapies, including bluebird bio/Celgene’s idecabtagene vicleucel and Janssen’s ciltacabtagene autoleucel (cilta-cel). We explore how payers approach reimbursement of CAR T-cell therapies for B-cell ALL and multiple myeloma and how reimbursement decisions impact therapy selection and prescribing among surveyed hematologist-oncologists.
· What role do CAR T-cell therapies play in the treatment of multiple myeloma and B-cell ALL?
· What are hematologist-oncologists' experience with the use of Kyrmiah so far?
· What strategies will payers use to control utilization and costs of CAR T-cell therapies as more come to market?
· What are hematologist-oncologists’ views on select emerging CAR T-cell therapies in late-phase development?
GEOGRAPHY: United States.
PRIMARY RESEARCH: Survey of 56 U.S. hematologist-oncologists and 40 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).
KEY DRUGS COVERED: Kymriah, Besponsa, Blincyto, Blenrep, Tecartus, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel)
- Executive Summary
- Access and prescribing.
- Special topic: Market Access Outlook for CAR T-Cell Therapy
- Opportunities and challenges for emerging therapies.
- Chimeric Antigen Receptor (CAR) T-Cell Therapy - Access & Reimbursement - Detailed, Expanded Analysis (US)
Author(s): Chris Lewis
Chris Lewis serves as primary research manager, U.S. Access and Reimbursement, with responsibility for coordination, content review and content generation of the market access and reimbursement insights at DRG. Content is based on online surveys of managed care organizations and physicians and expert analysis of reimbursement and prescribing patterns of key therapies treating various disease states.
Lewis was an analyst/senior analyst for the group’s HealthLeaders-InterStudy subsidiary for eight years, specializing in the managed care and pharmacy benefit management industries. Throughout her tenure, she has produced the Health Plan Analysis reports for California, New York, New Jersey, Connecticut, and Pennsylvania and authored DRG’s series of pharmacy benefit manager profiles. She has also conducted numerous webinars for the group. She is a seasoned journalist with a B.A. in communications from California State University, Sacramento.